#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=The well-characterized GWI symptoms are GI inflammatory disease , chronic fatigue , neuroinflammation , and cognitive impairment .
3-1	15-18	The	abstract[4]	new[4]	coref	3-6[6_4]
3-2	19-37	well-characterized	abstract[4]	new[4]	_	_
3-3	38-41	GWI	abstract|abstract[4]	new|new[4]	coref	5-20
3-4	42-50	symptoms	abstract[4]	new[4]	_	_
3-5	51-54	are	_	_	_	_
3-6	55-57	GI	place|abstract[6]	new|giv[6]	coref|coref|coref|coref	4-13|7-4[40_6]|4-13|7-4[40_6]
3-7	58-70	inflammatory	abstract[6]	giv[6]	_	_
3-8	71-78	disease	abstract[6]	giv[6]	_	_
3-9	79-80	,	abstract[6]	giv[6]	_	_
3-10	81-88	chronic	abstract[6]|abstract[7]	giv[6]|new[7]	_	_
3-11	89-96	fatigue	abstract[6]|abstract[7]	giv[6]|new[7]	_	_
3-12	97-98	,	abstract[6]	giv[6]	_	_
3-13	99-116	neuroinflammation	abstract[6]|abstract	giv[6]|new	coref	4-15
3-14	117-118	,	abstract[6]	giv[6]	_	_
3-15	119-122	and	abstract[6]	giv[6]	_	_
3-16	123-132	cognitive	abstract[6]|abstract[9]	giv[6]|new[9]	_	_
3-17	133-143	impairment	abstract[6]|abstract[9]	giv[6]|new[9]	_	_
3-18	144-145	.	_	_	_	_

#Text=The current study investigates a mechanistic analysis of the gut virome-bacteriome mediated GI and neuroinflammation .
4-1	146-149	The	abstract[10]	new[10]	_	_
4-2	150-157	current	abstract[10]	new[10]	_	_
4-3	158-163	study	abstract[10]	new[10]	_	_
4-4	164-176	investigates	_	_	_	_
4-5	177-178	a	abstract[11]	new[11]	coref	9-20[61_11]
4-6	179-190	mechanistic	abstract[11]	new[11]	_	_
4-7	191-199	analysis	abstract[11]	new[11]	_	_
4-8	200-202	of	abstract[11]	new[11]	_	_
4-9	203-206	the	abstract[11]|abstract[13]	new[11]|new[13]	_	_
4-10	207-210	gut	abstract[11]|abstract|abstract[13]	new[11]|new|new[13]	coref	7-5
4-11	211-228	virome-bacteriome	abstract[11]|abstract[13]	new[11]|new[13]	_	_
4-12	229-237	mediated	_	_	_	_
4-13	238-240	GI	abstract	giv	coref	9-14
4-14	241-244	and	_	_	_	_
4-15	245-262	neuroinflammation	abstract	giv	ana	5-5
4-16	263-264	.	_	_	_	_

#Text=To our knowledge , this is the first study that examined GW chemical-induced virome dysbiosis and bacteriome-virome interactions in GWI .
5-1	265-267	To	_	_	_	_
5-2	268-271	our	person|abstract[17]	acc|new[17]	ana|ana	6-2|6-2
5-3	272-281	knowledge	abstract[17]	new[17]	_	_
5-4	282-283	,	_	_	_	_
5-5	284-288	this	abstract	giv	coref	5-7[19_0]
5-6	289-291	is	_	_	_	_
5-7	292-295	the	abstract[19]	giv[19]	coref	6-2[27_19]
5-8	296-301	first	abstract[19]	giv[19]	_	_
5-9	302-307	study	abstract[19]	giv[19]	_	_
5-10	308-312	that	_	_	_	_
5-11	313-321	examined	_	_	_	_
5-12	322-324	GW	abstract|abstract[22]|abstract[23]	new|new[22]|new[23]	coref|coref|coref|coref|coref|coref|coref|coref|coref	6-10|6-14[32_22]|8-18[50_23]|6-10|6-14[32_22]|8-18[50_23]|6-10|6-14[32_22]|8-18[50_23]
5-13	325-341	chemical-induced	abstract[22]|abstract[23]	new[22]|new[23]	_	_
5-14	342-348	virome	abstract|abstract[22]|abstract[23]	new|new[22]|new[23]	coref	8-11[46_0]
5-15	349-358	dysbiosis	abstract[22]|abstract[23]	new[22]|new[23]	_	_
5-16	359-362	and	abstract[23]	new[23]	_	_
5-17	363-380	bacteriome-virome	abstract[23]|abstract[24]	new[23]|new[24]	_	_
5-18	381-393	interactions	abstract[23]|abstract[24]	new[23]|new[24]	_	_
5-19	394-396	in	abstract[23]|abstract[24]	new[23]|new[24]	_	_
5-20	397-400	GWI	abstract[23]|abstract[24]|place	new[23]|new[24]|giv	coref	7-11
5-21	401-402	.	_	_	_	_

#Text=In our previous study , we have shown that GW chemical exposure causes bacterial dysbiosis and that led to the loss of healthy gut bacteria such as Lactobacillus and Bifidobacterium .
6-1	403-405	In	_	_	_	_
6-2	406-409	our	person|abstract[27]	giv|giv[27]	ana|coref|ana|coref	6-6|9-1[53_27]|6-6|9-1[53_27]
6-3	410-418	previous	abstract[27]	giv[27]	_	_
6-4	419-424	study	abstract[27]	giv[27]	_	_
6-5	425-426	,	_	_	_	_
6-6	427-429	we	person	giv	ana	10-5
6-7	430-434	have	_	_	_	_
6-8	435-440	shown	_	_	_	_
6-9	441-445	that	_	_	_	_
6-10	446-448	GW	abstract|abstract[30]	giv|new[30]	coref|coref|coref|coref	11-10|11-9[76_30]|11-10|11-9[76_30]
6-11	449-457	chemical	abstract[30]	new[30]	_	_
6-12	458-466	exposure	abstract[30]	new[30]	_	_
6-13	467-473	causes	_	_	_	_
6-14	474-483	bacterial	substance|abstract[32]	new|giv[32]	coref|coref|coref|coref	7-1[38_32]|8-18|7-1[38_32]|8-18
6-15	484-493	dysbiosis	abstract[32]	giv[32]	_	_
6-16	494-497	and	_	_	_	_
6-17	498-502	that	_	_	_	_
6-18	503-506	led	_	_	_	_
6-19	507-509	to	_	_	_	_
6-20	510-513	the	event[33]	new[33]	_	_
6-21	514-518	loss	event[33]	new[33]	_	_
6-22	519-521	of	event[33]	new[33]	_	_
6-23	522-529	healthy	event[33]|animal[34]	new[33]|new[34]	_	_
6-24	530-533	gut	event[33]|animal[34]	new[33]|new[34]	_	_
6-25	534-542	bacteria	event[33]|animal[34]	new[33]|new[34]	_	_
6-26	543-547	such	event[33]|animal[34]	new[33]|new[34]	_	_
6-27	548-550	as	event[33]|animal[34]	new[33]|new[34]	_	_
6-28	551-564	Lactobacillus	event[33]|animal[34]|substance	new[33]|new[34]|new	_	_
6-29	565-568	and	event[33]|animal[34]	new[33]|new[34]	_	_
6-30	569-584	Bifidobacterium	event[33]|animal[34]|substance	new[33]|new[34]|new	_	_
6-31	585-586	.	_	_	_	_

#Text=Gut dysbiosis induced leaky gut symptoms and systemic inflammation in GWI .
7-1	587-590	Gut	person|abstract[38]	new|giv[38]	coref|coref|coref|coref	8-18[49_38]|21-1|8-18[49_38]|21-1
7-2	591-600	dysbiosis	abstract[38]	giv[38]	_	_
7-3	601-608	induced	_	_	_	_
7-4	609-614	leaky	abstract[40]	giv[40]	coref	20-34[0_40]
7-5	615-618	gut	abstract|abstract[40]	giv|giv[40]	coref	8-11
7-6	619-627	symptoms	abstract[40]	giv[40]	_	_
7-7	628-631	and	abstract[40]	giv[40]	_	_
7-8	632-640	systemic	abstract[40]|abstract[41]	giv[40]|new[41]	ana	8-6[0_41]
7-9	641-653	inflammation	abstract[40]|abstract[41]	giv[40]|new[41]	_	_
7-10	654-656	in	abstract[40]|abstract[41]	giv[40]|new[41]	_	_
7-11	657-660	GWI	abstract[40]|abstract[41]|place	giv[40]|new[41]|giv	coref	10-14
7-12	661-662	.	_	_	_	_

#Text=In a recent review , it has been reported that gut virome is the missing link between bacterial dysbiosis and host immunity .
8-1	663-665	In	_	_	_	_
8-2	666-667	a	abstract[43]	new[43]	_	_
8-3	668-674	recent	abstract[43]	new[43]	_	_
8-4	675-681	review	abstract[43]	new[43]	_	_
8-5	682-683	,	_	_	_	_
8-6	684-686	it	abstract	giv	coref	16-32[139_0]
8-7	687-690	has	_	_	_	_
8-8	691-695	been	_	_	_	_
8-9	696-704	reported	_	_	_	_
8-10	705-709	that	_	_	_	_
8-11	710-713	gut	abstract|abstract[46]	giv|giv[46]	coref|coref|coref|coref	8-14[47_46]|12-28|8-14[47_46]|12-28
8-12	714-720	virome	abstract[46]	giv[46]	_	_
8-13	721-723	is	_	_	_	_
8-14	724-727	the	abstract[47]	giv[47]	coref	9-9[55_47]
8-15	728-735	missing	abstract[47]	giv[47]	_	_
8-16	736-740	link	abstract[47]	giv[47]	_	_
8-17	741-748	between	abstract[47]	giv[47]	_	_
8-18	749-758	bacterial	abstract[47]|substance|abstract[49]|abstract[50]	giv[47]|giv|giv[49]|giv[50]	coref|coref|coref|coref|coref|coref	15-14[123_0]|16-14[132_49]|15-14[123_0]|16-14[132_49]|15-14[123_0]|16-14[132_49]
8-19	759-768	dysbiosis	abstract[47]|abstract[49]|abstract[50]	giv[47]|giv[49]|giv[50]	_	_
8-20	769-772	and	abstract[47]|abstract[50]	giv[47]|giv[50]	_	_
8-21	773-777	host	abstract[47]|abstract[50]|person|abstract[52]	giv[47]|giv[50]|new|new[52]	coref|coref	12-21[96_0]|12-21[96_0]
8-22	778-786	immunity	abstract[47]|abstract[50]|abstract[52]	giv[47]|giv[50]|new[52]	_	_
8-23	787-788	.	_	_	_	_

#Text=The same study also described the role of virome in TLR signaling and GI diseases and hence concluding that virome analysis may lead to a novel therapeutic strategy for GI complications .
9-1	789-792	The	abstract[53]	giv[53]	coref	10-1[65_53]
9-2	793-797	same	abstract[53]	giv[53]	_	_
9-3	798-803	study	abstract[53]	giv[53]	_	_
9-4	804-808	also	_	_	_	_
9-5	809-818	described	_	_	_	_
9-6	819-822	the	abstract[54]	new[54]	_	_
9-7	823-827	role	abstract[54]	new[54]	_	_
9-8	828-830	of	abstract[54]	new[54]	_	_
9-9	831-837	virome	abstract[54]|abstract[55]	new[54]|giv[55]	coref	9-20[0_55]
9-10	838-840	in	abstract[54]|abstract[55]	new[54]|giv[55]	_	_
9-11	841-844	TLR	abstract[54]|abstract[55]|abstract|abstract[57]	new[54]|giv[55]|new|new[57]	_	_
9-12	845-854	signaling	abstract[54]|abstract[55]|abstract[57]	new[54]|giv[55]|new[57]	_	_
9-13	855-858	and	abstract[54]|abstract[55]	new[54]|giv[55]	_	_
9-14	859-861	GI	abstract[54]|abstract[55]|object|abstract[59]	new[54]|giv[55]|giv|new[59]	coref|coref	9-30|9-30
9-15	862-870	diseases	abstract[54]|abstract[55]|abstract[59]	new[54]|giv[55]|new[59]	_	_
9-16	871-874	and	_	_	_	_
9-17	875-880	hence	_	_	_	_
9-18	881-891	concluding	_	_	_	_
9-19	892-896	that	_	_	_	_
9-20	897-903	virome	abstract|abstract[61]	giv|giv[61]	coref|coref	12-28[99_0]|12-28[99_0]
9-21	904-912	analysis	abstract[61]	giv[61]	_	_
9-22	913-916	may	_	_	_	_
9-23	917-921	lead	_	_	_	_
9-24	922-924	to	_	_	_	_
9-25	925-926	a	abstract[62]	new[62]	_	_
9-26	927-932	novel	abstract[62]	new[62]	_	_
9-27	933-944	therapeutic	abstract[62]	new[62]	_	_
9-28	945-953	strategy	abstract[62]	new[62]	_	_
9-29	954-957	for	abstract[62]	new[62]	_	_
9-30	958-960	GI	abstract[62]|abstract|abstract[64]	new[62]|giv|new[64]	coref|coref|coref|coref	16-19|18-11[160_64]|16-19|18-11[160_64]
9-31	961-974	complications	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-32	975-976	.	_	_	_	_

#Text=The above study prompted us to explore the role of enteric viruses in GWI pathology and as a probable therapeutic target .
10-1	977-980	The	abstract[65]	giv[65]	coref	11-2[73_65]
10-2	981-986	above	abstract[65]	giv[65]	_	_
10-3	987-992	study	abstract[65]	giv[65]	_	_
10-4	993-1001	prompted	_	_	_	_
10-5	1002-1004	us	person	giv	ana	11-6
10-6	1005-1007	to	_	_	_	_
10-7	1008-1015	explore	_	_	_	_
10-8	1016-1019	the	abstract[67]	new[67]	_	_
10-9	1020-1024	role	abstract[67]	new[67]	_	_
10-10	1025-1027	of	abstract[67]	new[67]	_	_
10-11	1028-1035	enteric	abstract[67]|object|object[69]	new[67]|new|new[69]	coref|coref|coref|coref	12-18[95_69]|14-11|12-18[95_69]|14-11
10-12	1036-1043	viruses	abstract[67]|object[69]	new[67]|new[69]	_	_
10-13	1044-1046	in	abstract[67]|object[69]	new[67]|new[69]	_	_
10-14	1047-1050	GWI	abstract[67]|object[69]|abstract|abstract[71]	new[67]|new[69]|giv|new[71]	coref|coref|coref|coref	12-31|20-32[177_71]|12-31|20-32[177_71]
10-15	1051-1060	pathology	abstract[67]|object[69]|abstract[71]	new[67]|new[69]|new[71]	_	_
10-16	1061-1064	and	abstract[67]	new[67]	_	_
10-17	1065-1067	as	abstract[67]	new[67]	_	_
10-18	1068-1069	a	abstract[67]|abstract[72]	new[67]|new[72]	_	_
10-19	1070-1078	probable	abstract[67]|abstract[72]	new[67]|new[72]	_	_
10-20	1079-1090	therapeutic	abstract[67]|abstract[72]	new[67]|new[72]	_	_
10-21	1091-1097	target	abstract[67]|abstract[72]	new[67]|new[72]	_	_
10-22	1098-1099	.	_	_	_	_

#Text=In the present study , we found that the GW chemical exposure led to an increase in virome richness and relative abundance of dsDNA bacteriophages Myoviridae , Siphoviridae , and Caudovirales and decreased relative abundance of ssDNA bacteriophages Microviridae .
11-1	1100-1102	In	_	_	_	_
11-2	1103-1106	the	abstract[73]	giv[73]	coref	16-51[0_73]
11-3	1107-1114	present	abstract[73]	giv[73]	_	_
11-4	1115-1120	study	abstract[73]	giv[73]	_	_
11-5	1121-1122	,	_	_	_	_
11-6	1123-1125	we	person	giv	ana	12-1
11-7	1126-1131	found	_	_	_	_
11-8	1132-1136	that	_	_	_	_
11-9	1137-1140	the	abstract[76]	giv[76]	_	_
11-10	1141-1143	GW	abstract|abstract[76]	giv|giv[76]	coref	25-10
11-11	1144-1152	chemical	abstract[76]	giv[76]	_	_
11-12	1153-1161	exposure	abstract[76]	giv[76]	_	_
11-13	1162-1165	led	_	_	_	_
11-14	1166-1168	to	_	_	_	_
11-15	1169-1171	an	abstract[77]	new[77]	_	_
11-16	1172-1180	increase	abstract[77]	new[77]	_	_
11-17	1181-1183	in	abstract[77]	new[77]	_	_
11-18	1184-1190	virome	abstract[77]|abstract[78]|abstract[79]	new[77]|new[78]|new[79]	coref|coref|coref|coref	25-9[213_78]|25-9[214_79]|25-9[213_78]|25-9[214_79]
11-19	1191-1199	richness	abstract[77]|abstract[78]|abstract[79]	new[77]|new[78]|new[79]	_	_
11-20	1200-1203	and	abstract[77]|abstract[79]	new[77]|new[79]	_	_
11-21	1204-1212	relative	abstract[77]|abstract[79]|abstract[80]	new[77]|new[79]|new[80]	_	_
11-22	1213-1222	abundance	abstract[77]|abstract[79]|abstract[80]	new[77]|new[79]|new[80]	_	_
11-23	1223-1225	of	abstract[77]|abstract[79]|abstract[80]	new[77]|new[79]|new[80]	_	_
11-24	1226-1231	dsDNA	abstract[77]|abstract[79]|abstract[80]|substance|object[83]	new[77]|new[79]|new[80]|new|new[83]	_	_
11-25	1232-1246	bacteriophages	abstract[77]|abstract[79]|abstract[80]|place|object[83]	new[77]|new[79]|new[80]|new|new[83]	coref	11-38
11-26	1247-1257	Myoviridae	abstract[77]|abstract[79]|abstract[80]|object[83]	new[77]|new[79]|new[80]|new[83]	_	_
11-27	1258-1259	,	abstract[77]|abstract[79]|abstract[80]	new[77]|new[79]|new[80]	_	_
11-28	1260-1272	Siphoviridae	abstract[77]|abstract[79]|abstract[80]|substance	new[77]|new[79]|new[80]|new	_	_
11-29	1273-1274	,	abstract[77]|abstract[79]|abstract[80]	new[77]|new[79]|new[80]	_	_
11-30	1275-1278	and	abstract[77]|abstract[79]|abstract[80]	new[77]|new[79]|new[80]	_	_
11-31	1279-1291	Caudovirales	abstract[77]|abstract[79]|abstract[80]|animal	new[77]|new[79]|new[80]|new	_	_
11-32	1292-1295	and	_	_	_	_
11-33	1296-1305	decreased	_	_	_	_
11-34	1306-1314	relative	abstract[86]	new[86]	_	_
11-35	1315-1324	abundance	abstract[86]	new[86]	_	_
11-36	1325-1327	of	abstract[86]	new[86]	_	_
11-37	1328-1333	ssDNA	abstract[86]|substance|object[89]	new[86]|new|new[89]	_	_
11-38	1334-1348	bacteriophages	abstract[86]|place|object[89]	new[86]|giv|new[89]	_	_
11-39	1349-1361	Microviridae	abstract[86]|object[89]	new[86]|new[89]	_	_
11-40	1362-1363	.	_	_	_	_

#Text=We used a broad-spectrum antiviral compound Ribavirin to test the hypothesis that ( a ) inhibition of gut viruses in the host may prove the role of gut virome in GWI and ( b ) antiviral treatment may help to reconstruct and restore the virome signature in GWI .
12-1	1364-1366	We	person	giv	ana	14-1
12-2	1367-1371	used	_	_	_	_
12-3	1372-1373	a	object[92]	new[92]	coref	13-1[0_92]
12-4	1374-1388	broad-spectrum	object[92]	new[92]	_	_
12-5	1389-1398	antiviral	object[92]	new[92]	_	_
12-6	1399-1407	compound	substance|object[92]	new|new[92]	_	_
12-7	1408-1417	Ribavirin	object[92]	new[92]	_	_
12-8	1418-1420	to	_	_	_	_
12-9	1421-1425	test	_	_	_	_
12-10	1426-1429	the	abstract[93]	new[93]	_	_
12-11	1430-1440	hypothesis	abstract[93]	new[93]	_	_
12-12	1441-1445	that	_	_	_	_
12-13	1446-1447	(	abstract[94]	new[94]	_	_
12-14	1448-1449	a	abstract[94]	new[94]	_	_
12-15	1450-1451	)	abstract[94]	new[94]	_	_
12-16	1452-1462	inhibition	abstract[94]	new[94]	_	_
12-17	1463-1465	of	abstract[94]	new[94]	_	_
12-18	1466-1469	gut	abstract[94]|object[95]	new[94]|giv[95]	coref	20-14[171_95]
12-19	1470-1477	viruses	abstract[94]|object[95]	new[94]|giv[95]	_	_
12-20	1478-1480	in	abstract[94]|object[95]	new[94]|giv[95]	_	_
12-21	1481-1484	the	abstract[94]|object[95]|person[96]	new[94]|giv[95]|giv[96]	coref	21-12[0_96]
12-22	1485-1489	host	abstract[94]|object[95]|person[96]	new[94]|giv[95]|giv[96]	_	_
12-23	1490-1493	may	_	_	_	_
12-24	1494-1499	prove	_	_	_	_
12-25	1500-1503	the	abstract[97]	new[97]	_	_
12-26	1504-1508	role	abstract[97]	new[97]	_	_
12-27	1509-1511	of	abstract[97]	new[97]	_	_
12-28	1512-1515	gut	abstract[97]|abstract|abstract[99]	new[97]|giv|giv[99]	coref|coref|coref|coref	12-45[0_99]|15-20[125_0]|12-45[0_99]|15-20[125_0]
12-29	1516-1522	virome	abstract[97]|abstract[99]	new[97]|giv[99]	_	_
12-30	1523-1525	in	abstract[97]|abstract[99]	new[97]|giv[99]	_	_
12-31	1526-1529	GWI	abstract[97]|abstract[99]|event	new[97]|giv[99]|giv	coref	12-48
12-32	1530-1533	and	_	_	_	_
12-33	1534-1535	(	_	_	_	_
12-34	1536-1537	b	place	new	_	_
12-35	1538-1539	)	_	_	_	_
12-36	1540-1549	antiviral	abstract[102]	new[102]	coref	17-7[150_102]
12-37	1550-1559	treatment	abstract[102]	new[102]	_	_
12-38	1560-1563	may	_	_	_	_
12-39	1564-1568	help	_	_	_	_
12-40	1569-1571	to	_	_	_	_
12-41	1572-1583	reconstruct	_	_	_	_
12-42	1584-1587	and	_	_	_	_
12-43	1588-1595	restore	_	_	_	_
12-44	1596-1599	the	abstract[104]	new[104]	_	_
12-45	1600-1606	virome	abstract|abstract[104]	giv|new[104]	coref	16-11[130_0]
12-46	1607-1616	signature	abstract[104]	new[104]	_	_
12-47	1617-1619	in	abstract[104]	new[104]	_	_
12-48	1620-1623	GWI	abstract[104]|abstract	new[104]|giv	coref	20-30
12-49	1624-1625	.	_	_	_	_

#Text=Ribavirin has been extensively used as a therapeutic drug in several viral infections including Paramyxovirus , Adenovirus , and RSV infections .
13-1	1626-1635	Ribavirin	object	giv	coref	14-5
13-2	1636-1639	has	_	_	_	_
13-3	1640-1644	been	_	_	_	_
13-4	1645-1656	extensively	_	_	_	_
13-5	1657-1661	used	_	_	_	_
13-6	1662-1664	as	_	_	_	_
13-7	1665-1666	a	_	_	_	_
13-8	1667-1678	therapeutic	_	_	_	_
13-9	1679-1683	drug	_	_	_	_
13-10	1684-1686	in	_	_	_	_
13-11	1687-1694	several	abstract[107]	new[107]	_	_
13-12	1695-1700	viral	abstract[107]	new[107]	_	_
13-13	1701-1711	infections	abstract[107]	new[107]	_	_
13-14	1712-1721	including	abstract[107]	new[107]	_	_
13-15	1722-1735	Paramyxovirus	abstract[107]|abstract	new[107]|new	_	_
13-16	1736-1737	,	abstract[107]	new[107]	_	_
13-17	1738-1748	Adenovirus	abstract[107]|place	new[107]|new	_	_
13-18	1749-1750	,	abstract[107]	new[107]	_	_
13-19	1751-1754	and	abstract[107]	new[107]	_	_
13-20	1755-1758	RSV	abstract[107]|object|abstract[111]	new[107]|new|new[111]	_	_
13-21	1759-1769	infections	abstract[107]|abstract[111]	new[107]|new[111]	_	_
13-22	1770-1771	.	_	_	_	_

#Text=Our results showed that Ribavirin reverses GWI-induced alterations of the enteric viral community .
14-1	1772-1775	Our	person|abstract[113]	giv|new[113]	ana|coref|ana|coref	16-3|19-1[0_113]|16-3|19-1[0_113]
14-2	1776-1783	results	abstract[113]	new[113]	_	_
14-3	1784-1790	showed	_	_	_	_
14-4	1791-1795	that	_	_	_	_
14-5	1796-1805	Ribavirin	substance	giv	coref	17-7
14-6	1806-1814	reverses	_	_	_	_
14-7	1815-1826	GWI-induced	abstract[115]	new[115]	_	_
14-8	1827-1838	alterations	abstract[115]	new[115]	_	_
14-9	1839-1841	of	abstract[115]	new[115]	_	_
14-10	1842-1845	the	abstract[115]|abstract[117]	new[115]|new[117]	coref	15-17[124_117]
14-11	1846-1853	enteric	abstract[115]|person|abstract[117]	new[115]|giv|new[117]	coref	15-2
14-12	1854-1859	viral	abstract[115]|abstract[117]	new[115]|new[117]	_	_
14-13	1860-1869	community	abstract[115]|abstract[117]	new[115]|new[117]	_	_
14-14	1870-1871	.	_	_	_	_

#Text=The enteric bacteriophage-bacteria ( parasite-host ) interaction is an essential phenomenon to regulate both bacterial and viral community in the gut and play as a key role in gut health .
15-1	1872-1875	The	abstract[119]	new[119]	_	_
15-2	1876-1883	enteric	person|abstract[119]	giv|new[119]	coref	30-6
15-3	1884-1906	bacteriophage-bacteria	abstract[119]	new[119]	_	_
15-4	1907-1908	(	_	_	_	_
15-5	1909-1922	parasite-host	person	new	_	_
15-6	1923-1924	)	_	_	_	_
15-7	1925-1936	interaction	abstract	new	coref	15-9[122_0]
15-8	1937-1939	is	_	_	_	_
15-9	1940-1942	an	abstract[122]	giv[122]	_	_
15-10	1943-1952	essential	abstract[122]	giv[122]	_	_
15-11	1953-1963	phenomenon	abstract[122]	giv[122]	_	_
15-12	1964-1966	to	_	_	_	_
15-13	1967-1975	regulate	_	_	_	_
15-14	1976-1980	both	substance[123]	giv[123]	_	_
15-15	1981-1990	bacterial	substance[123]	giv[123]	_	_
15-16	1991-1994	and	_	_	_	_
15-17	1995-2000	viral	abstract[124]	giv[124]	_	_
15-18	2001-2010	community	abstract[124]	giv[124]	_	_
15-19	2011-2013	in	abstract[124]	giv[124]	_	_
15-20	2014-2017	the	abstract[124]|abstract[125]	giv[124]|giv[125]	coref	15-29[0_125]
15-21	2018-2021	gut	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
15-22	2022-2025	and	_	_	_	_
15-23	2026-2030	play	_	_	_	_
15-24	2031-2033	as	_	_	_	_
15-25	2034-2035	a	_	_	_	_
15-26	2036-2039	key	_	_	_	_
15-27	2040-2044	role	_	_	_	_
15-28	2045-2047	in	_	_	_	_
15-29	2048-2051	gut	abstract|abstract[127]	giv|new[127]	coref|coref	18-4|18-4
15-30	2052-2058	health	abstract[127]	new[127]	_	_
15-31	2059-2060	.	_	_	_	_

#Text=Here , we found an independent or cumulative effect of both virome and bacteriome dysbiosis in weakening of GI tight junctions ( increased Claudin-2 and decreased ZO1 and Occludin ) , GI inflammation ( increased MCP1 and IL6 ) , systemic inflammation ( increased serum IFNγ and IL6 ) and neuroinflammation ( increased microglia activation and brain IL6 ) .
16-1	2061-2065	Here	_	_	_	_
16-2	2066-2067	,	_	_	_	_
16-3	2068-2070	we	person	giv	ana	20-43
16-4	2071-2076	found	_	_	_	_
16-5	2077-2079	an	abstract[129]	new[129]	_	_
16-6	2080-2091	independent	abstract[129]	new[129]	_	_
16-7	2092-2094	or	abstract[129]	new[129]	_	_
16-8	2095-2105	cumulative	abstract[129]	new[129]	_	_
16-9	2106-2112	effect	abstract[129]	new[129]	_	_
16-10	2113-2115	of	abstract[129]	new[129]	_	_
16-11	2116-2120	both	abstract[129]|abstract[130]|abstract[131]	new[129]|giv[130]|new[131]	coref|coref|coref|coref	25-12[0_130]|26-55[247_131]|25-12[0_130]|26-55[247_131]
16-12	2121-2127	virome	abstract[129]|abstract[130]|abstract[131]	new[129]|giv[130]|new[131]	_	_
16-13	2128-2131	and	abstract[129]|abstract[131]	new[129]|new[131]	_	_
16-14	2132-2142	bacteriome	abstract[129]|abstract[131]|abstract[132]	new[129]|new[131]|giv[132]	coref	25-15[0_132]
16-15	2143-2152	dysbiosis	abstract[129]|abstract[131]|abstract[132]	new[129]|new[131]|giv[132]	_	_
16-16	2153-2155	in	_	_	_	_
16-17	2156-2165	weakening	abstract[133]	new[133]	_	_
16-18	2166-2168	of	abstract[133]	new[133]	_	_
16-19	2169-2171	GI	abstract[133]|place|person[135]	new[133]|giv|new[135]	appos|coref|appos|coref	16-23[137_135]|16-32|16-23[137_135]|16-32
16-20	2172-2177	tight	abstract[133]|person[135]	new[133]|new[135]	_	_
16-21	2178-2187	junctions	abstract[133]|person[135]	new[133]|new[135]	_	_
16-22	2188-2189	(	_	_	_	_
16-23	2190-2199	increased	substance[136]|place[137]	new[136]|giv[137]	_	_
16-24	2200-2209	Claudin-2	substance[136]|place[137]	new[136]|giv[137]	_	_
16-25	2210-2213	and	place[137]	giv[137]	_	_
16-26	2214-2223	decreased	place[137]	giv[137]	_	_
16-27	2224-2227	ZO1	place[137]	giv[137]	_	_
16-28	2228-2231	and	place[137]	giv[137]	_	_
16-29	2232-2240	Occludin	place[137]	giv[137]	_	_
16-30	2241-2242	)	_	_	_	_
16-31	2243-2244	,	_	_	_	_
16-32	2245-2247	GI	object|abstract[139]	giv|giv[139]	appos|coref|appos|coref	16-35[140_139]|17-10|16-35[140_139]|17-10
16-33	2248-2260	inflammation	abstract[139]	giv[139]	_	_
16-34	2261-2262	(	_	_	_	_
16-35	2263-2272	increased	abstract[140]	giv[140]	coref	16-41[141_140]
16-36	2273-2277	MCP1	abstract[140]	giv[140]	_	_
16-37	2278-2281	and	abstract[140]	giv[140]	_	_
16-38	2282-2285	IL6	abstract[140]	giv[140]	_	_
16-39	2286-2287	)	_	_	_	_
16-40	2288-2289	,	_	_	_	_
16-41	2290-2298	systemic	abstract[141]	giv[141]	coref	27-7[251_141]
16-42	2299-2311	inflammation	abstract[141]	giv[141]	_	_
16-43	2312-2313	(	abstract[141]	giv[141]	_	_
16-44	2314-2323	increased	abstract[141]	giv[141]	_	_
16-45	2324-2329	serum	abstract[141]|abstract|abstract[143]	giv[141]|new|new[143]	coref|coref	28-23|28-23
16-46	2330-2334	IFNγ	abstract[141]|abstract[143]	giv[141]|new[143]	_	_
16-47	2335-2338	and	abstract[141]	giv[141]	_	_
16-48	2339-2342	IL6	abstract[141]	giv[141]	_	_
16-49	2343-2344	)	abstract[141]	giv[141]	_	_
16-50	2345-2348	and	_	_	_	_
16-51	2349-2366	neuroinflammation	abstract	giv	appos	16-53[146_0]
16-52	2367-2368	(	_	_	_	_
16-53	2369-2378	increased	abstract[146]	giv[146]	coref	17-1[148_146]
16-54	2379-2388	microglia	place|abstract[146]	new|giv[146]	_	_
16-55	2389-2399	activation	abstract[146]	giv[146]	_	_
16-56	2400-2403	and	abstract[146]	giv[146]	_	_
16-57	2404-2409	brain	abstract[146]|object	giv[146]|new	_	_
16-58	2410-2413	IL6	abstract[146]	giv[146]	_	_
16-59	2414-2415	)	_	_	_	_
16-60	2416-2417	.	_	_	_	_

#Text=The present study also showed that Ribavirin treatment improved GI tight junction assembly and subsequently decreasing GI and neuroinflammation .
17-1	2418-2421	The	abstract[148]	giv[148]	coref	17-19[0_148]
17-2	2422-2429	present	abstract[148]	giv[148]	_	_
17-3	2430-2435	study	abstract[148]	giv[148]	_	_
17-4	2436-2440	also	_	_	_	_
17-5	2441-2447	showed	_	_	_	_
17-6	2448-2452	that	_	_	_	_
17-7	2453-2462	Ribavirin	substance|abstract[150]	giv|giv[150]	coref|coref	19-13|19-13
17-8	2463-2472	treatment	abstract[150]	giv[150]	_	_
17-9	2473-2481	improved	_	_	_	_
17-10	2482-2484	GI	abstract|organization[153]	giv|new[153]	coref|coref	17-17|17-17
17-11	2485-2490	tight	organization[153]	new[153]	_	_
17-12	2491-2499	junction	place|organization[153]	new|new[153]	_	_
17-13	2500-2508	assembly	organization[153]	new[153]	_	_
17-14	2509-2512	and	_	_	_	_
17-15	2513-2525	subsequently	_	_	_	_
17-16	2526-2536	decreasing	_	_	_	_
17-17	2537-2539	GI	abstract	giv	coref	18-11[159_0]
17-18	2540-2543	and	_	_	_	_
17-19	2544-2561	neuroinflammation	abstract	giv	coref	25-2[209_0]
17-20	2562-2563	.	_	_	_	_

#Text=Interestingly , inducing gut sterility by using antibiotics also improves such GI and neurological complications .
18-1	2564-2577	Interestingly	_	_	_	_
18-2	2578-2579	,	_	_	_	_
18-3	2580-2588	inducing	_	_	_	_
18-4	2589-2592	gut	abstract|abstract[157]	giv|new[157]	coref|coref	26-55|26-55
18-5	2593-2602	sterility	abstract[157]	new[157]	_	_
18-6	2603-2605	by	_	_	_	_
18-7	2606-2611	using	_	_	_	_
18-8	2612-2623	antibiotics	substance	new	coref	19-15
18-9	2624-2628	also	_	_	_	_
18-10	2629-2637	improves	_	_	_	_
18-11	2638-2642	such	abstract[159]|abstract[160]	giv[159]|giv[160]	coref|coref|coref|coref	19-22[0_159]|19-21[166_160]|19-22[0_159]|19-21[166_160]
18-12	2643-2645	GI	abstract[159]|abstract[160]	giv[159]|giv[160]	_	_
18-13	2646-2649	and	abstract[160]	giv[160]	_	_
18-14	2650-2662	neurological	abstract[160]	giv[160]	_	_
18-15	2663-2676	complications	abstract[160]	giv[160]	_	_
18-16	2677-2678	.	_	_	_	_

#Text=Results reported here are also strongly supported by previous such studies where Ribavirin or antibiotics were applied as therapeutics in other GI complications and neurological illnesses .
19-1	2679-2686	Results	abstract	giv	coref	28-1[257_0]
19-2	2687-2695	reported	_	_	_	_
19-3	2696-2700	here	_	_	_	_
19-4	2701-2704	are	_	_	_	_
19-5	2705-2709	also	_	_	_	_
19-6	2710-2718	strongly	_	_	_	_
19-7	2719-2728	supported	_	_	_	_
19-8	2729-2731	by	_	_	_	_
19-9	2732-2740	previous	abstract[162]	new[162]	_	_
19-10	2741-2745	such	abstract[162]	new[162]	_	_
19-11	2746-2753	studies	abstract[162]	new[162]	_	_
19-12	2754-2759	where	_	_	_	_
19-13	2760-2769	Ribavirin	substance	giv	coref	27-12
19-14	2770-2772	or	_	_	_	_
19-15	2773-2784	antibiotics	substance	giv	coref	27-14
19-16	2785-2789	were	_	_	_	_
19-17	2790-2797	applied	_	_	_	_
19-18	2798-2800	as	_	_	_	_
19-19	2801-2813	therapeutics	_	_	_	_
19-20	2814-2816	in	_	_	_	_
19-21	2817-2822	other	abstract[166]	giv[166]	_	_
19-22	2823-2825	GI	abstract|abstract[166]	giv|giv[166]	_	_
19-23	2826-2839	complications	abstract[166]	giv[166]	_	_
19-24	2840-2843	and	abstract[166]	giv[166]	_	_
19-25	2844-2856	neurological	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
19-26	2857-2866	illnesses	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
19-27	2867-2868	.	_	_	_	_

#Text=However , nonavailability of germ-free and gnotobiotic mice or mice completely devoid of gut viruses prove to be a serious handicap in establishing the exact role of viruses in GWI or any other disease pathology though use of antiviral cocktails similar to our approach have been shown to serve the purpose .
20-1	2869-2876	However	_	_	_	_
20-2	2877-2878	,	_	_	_	_
20-3	2879-2894	nonavailability	_	_	_	_
20-4	2895-2897	of	_	_	_	_
20-5	2898-2907	germ-free	object	new	_	_
20-6	2908-2911	and	_	_	_	_
20-7	2912-2923	gnotobiotic	animal[169]	new[169]	_	_
20-8	2924-2928	mice	animal[169]	new[169]	_	_
20-9	2929-2931	or	_	_	_	_
20-10	2932-2936	mice	animal[170]	new[170]	_	_
20-11	2937-2947	completely	animal[170]	new[170]	_	_
20-12	2948-2954	devoid	animal[170]	new[170]	_	_
20-13	2955-2957	of	_	_	_	_
20-14	2958-2961	gut	object[171]	giv[171]	coref	20-28[174_171]
20-15	2962-2969	viruses	object[171]	giv[171]	_	_
20-16	2970-2975	prove	_	_	_	_
20-17	2976-2978	to	_	_	_	_
20-18	2979-2981	be	_	_	_	_
20-19	2982-2983	a	abstract[172]	new[172]	_	_
20-20	2984-2991	serious	abstract[172]	new[172]	_	_
20-21	2992-3000	handicap	abstract[172]	new[172]	_	_
20-22	3001-3003	in	_	_	_	_
20-23	3004-3016	establishing	_	_	_	_
20-24	3017-3020	the	abstract[173]	new[173]	coref	32-27[293_173]
20-25	3021-3026	exact	abstract[173]	new[173]	_	_
20-26	3027-3031	role	abstract[173]	new[173]	_	_
20-27	3032-3034	of	abstract[173]	new[173]	_	_
20-28	3035-3042	viruses	abstract[173]|object[174]	new[173]|giv[174]	coref	30-5[273_174]
20-29	3043-3045	in	abstract[173]|object[174]	new[173]|giv[174]	_	_
20-30	3046-3049	GWI	abstract[173]|object[174]|event	new[173]|giv[174]|giv	coref	29-13
20-31	3050-3052	or	abstract[173]|object[174]	new[173]|giv[174]	_	_
20-32	3053-3056	any	abstract[173]|object[174]|abstract[177]	new[173]|giv[174]|giv[177]	coref	21-12[189_177]
20-33	3057-3062	other	abstract[173]|object[174]|abstract[177]	new[173]|giv[174]|giv[177]	_	_
20-34	3063-3070	disease	abstract[173]|object[174]|abstract|abstract[177]	new[173]|giv[174]|giv|giv[177]	_	_
20-35	3071-3080	pathology	abstract[173]|object[174]|abstract[177]	new[173]|giv[174]|giv[177]	_	_
20-36	3081-3087	though	_	_	_	_
20-37	3088-3091	use	abstract[178]	new[178]	_	_
20-38	3092-3094	of	abstract[178]	new[178]	_	_
20-39	3095-3104	antiviral	abstract[178]|object[179]	new[178]|new[179]	_	_
20-40	3105-3114	cocktails	abstract[178]|object[179]	new[178]|new[179]	_	_
20-41	3115-3122	similar	abstract[178]	new[178]	_	_
20-42	3123-3125	to	_	_	_	_
20-43	3126-3129	our	person|abstract[181]	giv|new[181]	ana|ana	25-5|25-5
20-44	3130-3138	approach	abstract[181]	new[181]	_	_
20-45	3139-3143	have	_	_	_	_
20-46	3144-3148	been	_	_	_	_
20-47	3149-3154	shown	_	_	_	_
20-48	3155-3157	to	_	_	_	_
20-49	3158-3163	serve	_	_	_	_
20-50	3164-3167	the	abstract[182]	new[182]	_	_
20-51	3168-3175	purpose	abstract[182]	new[182]	_	_
20-52	3176-3177	.	_	_	_	_

#Text=Gut microbiome is a collection of trillions of microorganisms that modulated host pathology and physiology through different mechanisms .
21-1	3178-3181	Gut	person|abstract[184]	giv|new[184]	coref|coref	21-4[185_184]|21-4[185_184]
21-2	3182-3192	microbiome	abstract[184]	new[184]	_	_
21-3	3193-3195	is	_	_	_	_
21-4	3196-3197	a	abstract[185]	giv[185]	coref	23-6[0_185]
21-5	3198-3208	collection	abstract[185]	giv[185]	_	_
21-6	3209-3211	of	abstract[185]	giv[185]	_	_
21-7	3212-3221	trillions	abstract[185]|person[186]	giv[185]|new[186]	_	_
21-8	3222-3224	of	abstract[185]|person[186]	giv[185]|new[186]	_	_
21-9	3225-3239	microorganisms	abstract[185]|person[186]|abstract	giv[185]|new[186]|new	_	_
21-10	3240-3244	that	_	_	_	_
21-11	3245-3254	modulated	_	_	_	_
21-12	3255-3259	host	person|abstract[189]	giv|giv[189]	coref|coref	32-36[296_0]|32-36[296_0]
21-13	3260-3269	pathology	abstract[189]	giv[189]	_	_
21-14	3270-3273	and	_	_	_	_
21-15	3274-3284	physiology	abstract	new	_	_
21-16	3285-3292	through	_	_	_	_
21-17	3293-3302	different	abstract[191]	new[191]	coref	32-33[295_191]
21-18	3303-3313	mechanisms	abstract[191]	new[191]	_	_
21-19	3314-3315	.	_	_	_	_

#Text=Previous reports have suggested that the intestinal microbiota had a strong influence on the mucosal immune system and vice versa .
22-1	3316-3324	Previous	abstract[192]	new[192]	_	_
22-2	3325-3332	reports	abstract[192]	new[192]	_	_
22-3	3333-3337	have	_	_	_	_
22-4	3338-3347	suggested	_	_	_	_
22-5	3348-3352	that	_	_	_	_
22-6	3353-3356	the	object[194]	new[194]	_	_
22-7	3357-3367	intestinal	person|object[194]	new|new[194]	_	_
22-8	3368-3378	microbiota	object[194]	new[194]	_	_
22-9	3379-3382	had	_	_	_	_
22-10	3383-3384	a	abstract[195]	new[195]	_	_
22-11	3385-3391	strong	abstract[195]	new[195]	_	_
22-12	3392-3401	influence	abstract[195]	new[195]	_	_
22-13	3402-3404	on	abstract[195]	new[195]	_	_
22-14	3405-3408	the	abstract[195]|abstract[197]	new[195]|new[197]	_	_
22-15	3409-3416	mucosal	abstract[195]|abstract[197]	new[195]|new[197]	_	_
22-16	3417-3423	immune	abstract[195]|abstract|abstract[197]	new[195]|new|new[197]	coref	23-11
22-17	3424-3430	system	abstract[195]|abstract[197]	new[195]|new[197]	_	_
22-18	3431-3434	and	abstract[195]	new[195]	_	_
22-19	3435-3439	vice	abstract[195]|person[198]	new[195]|new[198]	_	_
22-20	3440-3445	versa	abstract[195]|person[198]	new[195]|new[198]	_	_
22-21	3446-3447	.	_	_	_	_

#Text=A balanced pathogen and commensal microbiome composition maintain the microbiome-host immune homeostasis .
23-1	3448-3449	A	abstract[199]	new[199]	_	_
23-2	3450-3458	balanced	abstract[199]	new[199]	_	_
23-3	3459-3467	pathogen	abstract[199]	new[199]	_	_
23-4	3468-3471	and	_	_	_	_
23-5	3472-3481	commensal	abstract[201]	new[201]	_	_
23-6	3482-3492	microbiome	abstract|abstract[201]	giv|new[201]	coref	24-6[205_0]
23-7	3493-3504	composition	abstract[201]	new[201]	_	_
23-8	3505-3513	maintain	_	_	_	_
23-9	3514-3517	the	abstract[203]	new[203]	_	_
23-10	3518-3533	microbiome-host	abstract[203]	new[203]	_	_
23-11	3534-3540	immune	abstract|abstract[203]	giv|new[203]	coref	24-13
23-12	3541-3552	homeostasis	abstract[203]	new[203]	_	_
23-13	3553-3554	.	_	_	_	_

#Text=However , any alteration in the microbiome may activate innate and adaptive immune responses and may progress to an inflammatory phenotype .
24-1	3555-3562	However	_	_	_	_
24-2	3563-3564	,	_	_	_	_
24-3	3565-3568	any	abstract[204]	new[204]	_	_
24-4	3569-3579	alteration	abstract[204]	new[204]	_	_
24-5	3580-3582	in	abstract[204]	new[204]	_	_
24-6	3583-3586	the	abstract[204]|abstract[205]	new[204]|giv[205]	coref	26-58[0_205]
24-7	3587-3597	microbiome	abstract[204]|abstract[205]	new[204]|giv[205]	_	_
24-8	3598-3601	may	_	_	_	_
24-9	3602-3610	activate	_	_	_	_
24-10	3611-3617	innate	abstract[207]	new[207]	_	_
24-11	3618-3621	and	abstract[207]	new[207]	_	_
24-12	3622-3630	adaptive	abstract[207]	new[207]	_	_
24-13	3631-3637	immune	abstract|abstract[207]	giv|new[207]	_	_
24-14	3638-3647	responses	abstract[207]	new[207]	_	_
24-15	3648-3651	and	_	_	_	_
24-16	3652-3655	may	_	_	_	_
24-17	3656-3664	progress	_	_	_	_
24-18	3665-3667	to	_	_	_	_
24-19	3668-3670	an	abstract[208]	new[208]	_	_
24-20	3671-3683	inflammatory	abstract[208]	new[208]	_	_
24-21	3684-3693	phenotype	abstract[208]	new[208]	_	_
24-22	3694-3695	.	_	_	_	_

#Text=In the present study we have shown that the GW chemical-induced virome richness and dysbiosis showed a strong association with activated Toll-like receptor-7 ( TLR7 ) and TLR9 mediated proinflammatory pathways .
25-1	3696-3698	In	_	_	_	_
25-2	3699-3702	the	abstract[209]	giv[209]	coref	26-8[224_209]
25-3	3703-3710	present	abstract[209]	giv[209]	_	_
25-4	3711-3716	study	abstract[209]	giv[209]	_	_
25-5	3717-3719	we	person	giv	ana	26-1
25-6	3720-3724	have	_	_	_	_
25-7	3725-3730	shown	_	_	_	_
25-8	3731-3735	that	_	_	_	_
25-9	3736-3739	the	abstract[213]|abstract[214]	giv[213]|giv[214]	_	_
25-10	3740-3742	GW	abstract|abstract[213]|abstract[214]	giv|giv[213]|giv[214]	_	_
25-11	3743-3759	chemical-induced	abstract[213]|abstract[214]	giv[213]|giv[214]	_	_
25-12	3760-3766	virome	abstract|abstract[213]|abstract[214]	giv|giv[213]|giv[214]	coref	26-55[246_0]
25-13	3767-3775	richness	abstract[213]|abstract[214]	giv[213]|giv[214]	_	_
25-14	3776-3779	and	abstract[214]	giv[214]	_	_
25-15	3780-3789	dysbiosis	abstract[214]|abstract	giv[214]|giv	coref	26-58[249_0]
25-16	3790-3796	showed	_	_	_	_
25-17	3797-3798	a	abstract[216]	new[216]	_	_
25-18	3799-3805	strong	abstract[216]	new[216]	_	_
25-19	3806-3817	association	abstract[216]	new[216]	_	_
25-20	3818-3822	with	abstract[216]	new[216]	_	_
25-21	3823-3832	activated	abstract[216]|abstract[218]	new[216]|new[218]	appos	25-25[0_218]
25-22	3833-3842	Toll-like	abstract[216]|abstract|abstract[218]	new[216]|new|new[218]	_	_
25-23	3843-3853	receptor-7	abstract[216]|abstract[218]	new[216]|new[218]	_	_
25-24	3854-3855	(	_	_	_	_
25-25	3856-3860	TLR7	abstract	giv	coref	26-18
25-26	3861-3862	)	_	_	_	_
25-27	3863-3866	and	_	_	_	_
25-28	3867-3871	TLR9	abstract	new	_	_
25-29	3872-3880	mediated	_	_	_	_
25-30	3881-3896	proinflammatory	abstract[221]	new[221]	coref	27-17[255_221]
25-31	3897-3905	pathways	abstract[221]	new[221]	_	_
25-32	3906-3907	.	_	_	_	_

#Text=We also found that the expression and activation of downstream signaling molecules including TLR7-MyD88 ( binding of TLR7 with adaptor molecule myosin D88 ) , TLR9-MyD88 , or TLR4-Flottilin ( localization of TLR4 in lipid raft ) complex formation , TRAF6 , IKK-α , and p65 ( NFκB activation ) have been increased upon gut virome and microbiome dysbiosis .
26-1	3908-3910	We	person	giv	ana	28-5
26-2	3911-3915	also	_	_	_	_
26-3	3916-3921	found	_	_	_	_
26-4	3922-3926	that	_	_	_	_
26-5	3927-3930	the	abstract[223]	new[223]	_	_
26-6	3931-3941	expression	abstract[223]	new[223]	_	_
26-7	3942-3945	and	_	_	_	_
26-8	3946-3956	activation	abstract[224]	giv[224]	coref	28-22[264_224]
26-9	3957-3959	of	abstract[224]	giv[224]	_	_
26-10	3960-3970	downstream	abstract[224]	giv[224]	_	_
26-11	3971-3980	signaling	_	_	_	_
26-12	3981-3990	molecules	object[225]	new[225]	_	_
26-13	3991-4000	including	object[225]	new[225]	_	_
26-14	4001-4011	TLR7-MyD88	object[225]|abstract	new[225]|new	_	_
26-15	4012-4013	(	object[225]	new[225]	_	_
26-16	4014-4021	binding	object[225]|object[227]	new[225]|new[227]	_	_
26-17	4022-4024	of	object[225]|object[227]	new[225]|new[227]	_	_
26-18	4025-4029	TLR7	object[225]|object[227]|abstract	new[225]|new[227]|giv	_	_
26-19	4030-4034	with	object[225]|object[227]	new[225]|new[227]	_	_
26-20	4035-4042	adaptor	object[225]|object[227]|substance|abstract[230]	new[225]|new[227]|new|new[230]	appos|appos	26-22[232_230]|26-22[232_230]
26-21	4043-4051	molecule	object[225]|object[227]|abstract[230]	new[225]|new[227]|new[230]	_	_
26-22	4052-4058	myosin	object[225]|person|abstract[232]	new[225]|new|giv[232]	_	_
26-23	4059-4062	D88	object[225]|abstract[232]	new[225]|giv[232]	_	_
26-24	4063-4064	)	object[225]	new[225]	_	_
26-25	4065-4066	,	object[225]	new[225]	_	_
26-26	4067-4077	TLR9-MyD88	object[225]|abstract	new[225]|new	_	_
26-27	4078-4079	,	object[225]	new[225]	_	_
26-28	4080-4082	or	object[225]	new[225]	_	_
26-29	4083-4097	TLR4-Flottilin	object[225]|abstract	new[225]|new	_	_
26-30	4098-4099	(	_	_	_	_
26-31	4100-4112	localization	abstract[235]	new[235]	_	_
26-32	4113-4115	of	abstract[235]	new[235]	_	_
26-33	4116-4120	TLR4	abstract[235]|abstract	new[235]|new	_	_
26-34	4121-4123	in	abstract[235]	new[235]	_	_
26-35	4124-4129	lipid	abstract[235]|abstract|object[238]	new[235]|new|new[238]	_	_
26-36	4130-4134	raft	abstract[235]|object[238]	new[235]|new[238]	_	_
26-37	4135-4136	)	_	_	_	_
26-38	4137-4144	complex	abstract[239]	new[239]	_	_
26-39	4145-4154	formation	abstract[239]	new[239]	_	_
26-40	4155-4156	,	_	_	_	_
26-41	4157-4162	TRAF6	abstract	new	_	_
26-42	4163-4164	,	_	_	_	_
26-43	4165-4170	IKK-α	object	new	_	_
26-44	4171-4172	,	_	_	_	_
26-45	4173-4176	and	_	_	_	_
26-46	4177-4180	p65	abstract	new	appos	26-48[244_0]
26-47	4181-4182	(	_	_	_	_
26-48	4183-4187	NFκB	abstract|abstract[244]	new|giv[244]	coref|coref	31-10[282_244]|31-10[282_244]
26-49	4188-4198	activation	abstract[244]	giv[244]	_	_
26-50	4199-4200	)	_	_	_	_
26-51	4201-4205	have	_	_	_	_
26-52	4206-4210	been	_	_	_	_
26-53	4211-4220	increased	_	_	_	_
26-54	4221-4225	upon	_	_	_	_
26-55	4226-4229	gut	abstract|abstract[246]|abstract[247]	giv|giv[246]|giv[247]	_	_
26-56	4230-4236	virome	abstract[246]|abstract[247]	giv[246]|giv[247]	_	_
26-57	4237-4240	and	abstract[247]	giv[247]	_	_
26-58	4241-4251	microbiome	abstract[247]|abstract|abstract[249]	giv[247]|giv|giv[249]	coref|coref	27-1[250_249]|27-1[250_249]
26-59	4252-4261	dysbiosis	abstract[247]|abstract[249]	giv[247]|giv[249]	_	_
26-60	4262-4263	.	_	_	_	_

#Text=The dysbiosis was also accompanied by increased inflammation while use of Ribavirin or antibiotics independently downregulated these pathways and subsequently inflammation .
27-1	4264-4267	The	abstract[250]	giv[250]	_	_
27-2	4268-4277	dysbiosis	abstract[250]	giv[250]	_	_
27-3	4278-4281	was	_	_	_	_
27-4	4282-4286	also	_	_	_	_
27-5	4287-4298	accompanied	_	_	_	_
27-6	4299-4301	by	_	_	_	_
27-7	4302-4311	increased	abstract[251]	giv[251]	coref	27-20[256_251]
27-8	4312-4324	inflammation	abstract[251]	giv[251]	_	_
27-9	4325-4330	while	_	_	_	_
27-10	4331-4334	use	abstract[252]	new[252]	_	_
27-11	4335-4337	of	abstract[252]	new[252]	_	_
27-12	4338-4347	Ribavirin	abstract[252]|substance	new[252]|giv	_	_
27-13	4348-4350	or	abstract[252]	new[252]	_	_
27-14	4351-4362	antibiotics	abstract[252]|substance	new[252]|giv	_	_
27-15	4363-4376	independently	_	_	_	_
27-16	4377-4390	downregulated	_	_	_	_
27-17	4391-4396	these	abstract[255]	giv[255]	_	_
27-18	4397-4405	pathways	abstract[255]	giv[255]	_	_
27-19	4406-4409	and	abstract[255]	giv[255]	_	_
27-20	4410-4422	subsequently	abstract[255]|abstract[256]	giv[255]|giv[256]	coref	28-22[263_256]
27-21	4423-4435	inflammation	abstract[255]|abstract[256]	giv[255]|giv[256]	_	_
27-22	4436-4437	.	_	_	_	_

#Text=The above results prompted us to study whether virome diversity had a direct connection to a sustained systemic inflammatory response via increased serum IL6 or vice versa .
28-1	4438-4441	The	abstract[257]	giv[257]	_	_
28-2	4442-4447	above	abstract[257]	giv[257]	_	_
28-3	4448-4455	results	abstract[257]	giv[257]	_	_
28-4	4456-4464	prompted	_	_	_	_
28-5	4465-4467	us	person	giv	ana	29-1
28-6	4468-4470	to	_	_	_	_
28-7	4471-4476	study	_	_	_	_
28-8	4477-4484	whether	_	_	_	_
28-9	4485-4491	virome	abstract[259]	new[259]	coref	29-6[268_259]
28-10	4492-4501	diversity	abstract[259]	new[259]	_	_
28-11	4502-4505	had	_	_	_	_
28-12	4506-4507	a	abstract[260]	new[260]	_	_
28-13	4508-4514	direct	abstract[260]	new[260]	_	_
28-14	4515-4525	connection	abstract[260]	new[260]	_	_
28-15	4526-4528	to	abstract[260]	new[260]	_	_
28-16	4529-4530	a	abstract[260]|abstract[261]	new[260]|new[261]	coref	30-15[276_261]
28-17	4531-4540	sustained	abstract[260]|abstract[261]	new[260]|new[261]	_	_
28-18	4541-4549	systemic	abstract[260]|abstract[261]	new[260]|new[261]	_	_
28-19	4550-4562	inflammatory	abstract[260]|abstract[261]	new[260]|new[261]	_	_
28-20	4563-4571	response	abstract[260]|abstract[261]	new[260]|new[261]	_	_
28-21	4572-4575	via	abstract[260]|abstract[261]	new[260]|new[261]	_	_
28-22	4576-4585	increased	abstract[260]|abstract[261]|abstract[263]|abstract[264]	new[260]|new[261]|giv[263]|giv[264]	coref|coref|coref|coref	29-4[0_263]|29-4[267_264]|29-4[0_263]|29-4[267_264]
28-23	4586-4591	serum	abstract[260]|abstract[261]|abstract|abstract[263]|abstract[264]	new[260]|new[261]|giv|giv[263]|giv[264]	_	_
28-24	4592-4595	IL6	abstract[260]|abstract[261]|abstract[263]|abstract[264]	new[260]|new[261]|giv[263]|giv[264]	_	_
28-25	4596-4598	or	abstract[260]|abstract[261]|abstract[264]	new[260]|new[261]|giv[264]	_	_
28-26	4599-4603	vice	abstract[260]|abstract[261]|abstract[264]	new[260]|new[261]|giv[264]	_	_
28-27	4604-4609	versa	abstract[260]|abstract[261]|abstract[264]	new[260]|new[261]|giv[264]	_	_
28-28	4610-4611	.	_	_	_	_

#Text=We found that IL6 and virome diversity had a positive correlation in GWI .
29-1	4612-4614	We	person	giv	ana	32-2
29-2	4615-4620	found	_	_	_	_
29-3	4621-4625	that	_	_	_	_
29-4	4626-4629	IL6	abstract|abstract[267]	giv|giv[267]	coref|coref|coref|coref	32-2[286_267]|32-16|32-2[286_267]|32-16
29-5	4630-4633	and	abstract[267]	giv[267]	_	_
29-6	4634-4640	virome	abstract[267]|abstract[268]	giv[267]|giv[268]	_	_
29-7	4641-4650	diversity	abstract[267]|abstract[268]	giv[267]|giv[268]	_	_
29-8	4651-4654	had	_	_	_	_
29-9	4655-4656	a	abstract[269]	new[269]	_	_
29-10	4657-4665	positive	abstract[269]	new[269]	_	_
29-11	4666-4677	correlation	abstract[269]	new[269]	_	_
29-12	4678-4680	in	abstract[269]	new[269]	_	_
29-13	4681-4684	GWI	abstract[269]|event	new[269]|giv	coref	32-31
29-14	4685-4686	.	_	_	_	_

#Text=Studies have shown that the enteric viruses can activate TLR3 signaling pathway to induce anti-inflammatory response via IFNβ production .
30-1	4687-4694	Studies	event	new	_	_
30-2	4695-4699	have	_	_	_	_
30-3	4700-4705	shown	_	_	_	_
30-4	4706-4710	that	_	_	_	_
30-5	4711-4714	the	object[273]	giv[273]	_	_
30-6	4715-4722	enteric	object|object[273]	giv|giv[273]	_	_
30-7	4723-4730	viruses	object[273]	giv[273]	_	_
30-8	4731-4734	can	_	_	_	_
30-9	4735-4743	activate	_	_	_	_
30-10	4744-4748	TLR3	abstract|abstract[275]	new|new[275]	coref|ana|coref|ana	31-11|32-27[0_275]|31-11|32-27[0_275]
30-11	4749-4758	signaling	abstract[275]	new[275]	_	_
30-12	4759-4766	pathway	abstract[275]	new[275]	_	_
30-13	4767-4769	to	_	_	_	_
30-14	4770-4776	induce	_	_	_	_
30-15	4777-4794	anti-inflammatory	abstract[276]	giv[276]	coref	31-15[283_276]
30-16	4795-4803	response	abstract[276]	giv[276]	_	_
30-17	4804-4807	via	abstract[276]	giv[276]	_	_
30-18	4808-4812	IFNβ	abstract[276]|object|abstract[278]	giv[276]|new|new[278]	ana|coref|ana|coref	31-3[0_278]|32-21[291_0]|31-3[0_278]|32-21[291_0]
30-19	4813-4823	production	abstract[276]|abstract[278]	giv[276]|new[278]	_	_
30-20	4824-4825	.	_	_	_	_

#Text=However , it has always been a conflict whether viral-induced TLR3 activation leads to pro- or anti-inflammatory response in viral pathogenesis .
31-1	4826-4833	However	_	_	_	_
31-2	4834-4835	,	_	_	_	_
31-3	4836-4838	it	event	giv	coref	31-7[280_0]
31-4	4839-4842	has	_	_	_	_
31-5	4843-4849	always	_	_	_	_
31-6	4850-4854	been	_	_	_	_
31-7	4855-4856	a	event[280]	giv[280]	_	_
31-8	4857-4865	conflict	event[280]	giv[280]	_	_
31-9	4866-4873	whether	_	_	_	_
31-10	4874-4887	viral-induced	abstract[282]	giv[282]	_	_
31-11	4888-4892	TLR3	abstract|abstract[282]	giv|giv[282]	coref	32-9
31-12	4893-4903	activation	abstract[282]	giv[282]	_	_
31-13	4904-4909	leads	_	_	_	_
31-14	4910-4912	to	_	_	_	_
31-15	4913-4917	pro-	abstract[283]	giv[283]	coref	32-13[289_283]
31-16	4918-4920	or	abstract[283]	giv[283]	_	_
31-17	4921-4938	anti-inflammatory	abstract[283]	giv[283]	_	_
31-18	4939-4947	response	abstract[283]	giv[283]	_	_
31-19	4948-4950	in	abstract[283]	giv[283]	_	_
31-20	4951-4956	viral	abstract[283]|abstract[284]	giv[283]|new[284]	_	_
31-21	4957-4969	pathogenesis	abstract[283]|abstract[284]	giv[283]|new[284]	_	_
31-22	4970-4971	.	_	_	_	_

#Text=In our study , we observed that increased TLR3 might switch to pro-inflammatory response via IL6 or fail to produce significant IFNβ in order to support its anti-inflammatory role in GWI though such mechanisms in the host remain inconclusive at this time .
32-1	4972-4974	In	_	_	_	_
32-2	4975-4978	our	person|abstract[286]	giv|giv[286]	ana|ana	32-5|32-5
32-3	4979-4984	study	abstract[286]	giv[286]	_	_
32-4	4985-4986	,	_	_	_	_
32-5	4987-4989	we	person	giv	_	_
32-6	4990-4998	observed	_	_	_	_
32-7	4999-5003	that	_	_	_	_
32-8	5004-5013	increased	_	_	_	_
32-9	5014-5018	TLR3	abstract	giv	_	_
32-10	5019-5024	might	_	_	_	_
32-11	5025-5031	switch	_	_	_	_
32-12	5032-5034	to	_	_	_	_
32-13	5035-5051	pro-inflammatory	abstract[289]	giv[289]	_	_
32-14	5052-5060	response	abstract[289]	giv[289]	_	_
32-15	5061-5064	via	abstract[289]	giv[289]	_	_
32-16	5065-5068	IL6	abstract[289]|abstract	giv[289]|giv	_	_
32-17	5069-5071	or	_	_	_	_
32-18	5072-5076	fail	_	_	_	_
32-19	5077-5079	to	_	_	_	_
32-20	5080-5087	produce	_	_	_	_
32-21	5088-5099	significant	object[291]	giv[291]	_	_
32-22	5100-5104	IFNβ	object[291]	giv[291]	_	_
32-23	5105-5107	in	_	_	_	_
32-24	5108-5113	order	_	_	_	_
32-25	5114-5116	to	_	_	_	_
32-26	5117-5124	support	_	_	_	_
32-27	5125-5128	its	abstract|abstract[293]	giv|giv[293]	_	_
32-28	5129-5146	anti-inflammatory	abstract[293]	giv[293]	_	_
32-29	5147-5151	role	abstract[293]	giv[293]	_	_
32-30	5152-5154	in	abstract[293]	giv[293]	_	_
32-31	5155-5158	GWI	abstract[293]|event	giv[293]|giv	_	_
32-32	5159-5165	though	_	_	_	_
32-33	5166-5170	such	abstract[295]	giv[295]	_	_
32-34	5171-5181	mechanisms	abstract[295]	giv[295]	_	_
32-35	5182-5184	in	abstract[295]	giv[295]	_	_
32-36	5185-5188	the	abstract[295]|place[296]	giv[295]|giv[296]	_	_
32-37	5189-5193	host	abstract[295]|place[296]	giv[295]|giv[296]	_	_
32-38	5194-5200	remain	_	_	_	_
32-39	5201-5213	inconclusive	_	_	_	_
32-40	5214-5216	at	_	_	_	_
32-41	5217-5221	this	_	_	_	_
32-42	5222-5226	time	_	_	_	_
32-43	5227-5228	.	_	_	_	_
